Accessed:10.03.2020

Accessed: 10.03.2020

MSF provides treatment for HIV and tuberculosis (TB) in more than 20 countries around the world. The report Burden sharing or burden shifting? How the HIV/TB response is being derailed examines the situation in nine countries where MSF runs programmes: Central African Republic, Democratic Republic of Congo, Eswatini, Guinea, Kenya, Malawi, Mozambique, Myanmar and Zimbabwe. With a focus on the financial resources available, this report highlights the current risks and gaps in HIV and TB service delivery in these countries. Given the findings of gaps in diagnosis, prevention and care services and dwindling resources, MSF calls for a robust assessment of the needs and the resource capacity of each affected country, and calls on international donors to ensure that the financial burden is shared, rather than shifted onto those countries worst affected by the diseases

People living with HIV who have a low CD4 count are at a much higher risk of falling ill from TB infection than HIV negative people. It is important to offer both HIV testing to TB patients and TB diagnosis in HIV patients. Early detection and effective treatment are essential to preventing TB-associated deaths. WHO and UNAIDS have strongly advised countries to ensure that HIV programmes integrate regular TB screening, preventive therapy and early treatment

Tuberculosis (TB) is the leading cause of illness and death among people living with HIV. TB can be cured.

PLOS ONE | https://doi.org/10.1371/journal.pone.0203986 October 3, 2018

“It has never been more urgent for us to come together to end HIV and tuberculosis. We achieve the most when we work together, using all of our strengths, harnessing all of our collective potential to end HIV and tuberculosis for a healthier world as part of the Sustainable Development Goals.” —Michel Sisibé, Executive Director of UNAID

Monitoring of implementation of collaborative TB/HIV activities and evaluation of impact is critically important. This requires efficient monitoring and evaluation system so as to establish accountability mechanisms between programmes, the population they serve, and donors. The Guide to monitoring and evaluation for collaborative TB/HIV activities will facilitate this process. The first version of the guide was developed in 2004 placing collaborative TB/HIV activities as integral part of national TB/HIV response. It was revised in 2009 to harmonize the approaches and indicators for monitoring and evaluation across key stakeholders. The current revision builds upon remarkable progress in implementation of collaborative TB/HIV activities and aims to strengthen the implementation further through improved quality of data